Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Summary: Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urge...

Full description

Bibliographic Details
Main Authors: Michael D. Nyquist, Alexandra Corella, Ilsa Coleman, Navonil De Sarkar, Arja Kaipainen, Gavin Ha, Roman Gulati, Lisa Ang, Payel Chatterjee, Jared Lucas, Colin Pritchard, Gail Risbridger, John Isaacs, Bruce Montgomery, Colm Morrissey, Eva Corey, Peter S. Nelson
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Cell Reports
Subjects:
prostate cancer
androgen receptor
TP53
RB1
plasticity
antiandrogen
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124720306227

Internet

http://www.sciencedirect.com/science/article/pii/S2211124720306227

Similar Items